PROPYLTHIOURACIL (propylthiouracil) by Pfizer is thyroid hormone synthesis inhibitors [moa]. First approved in 1947.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
Propylthiouracil (PTU) is an oral small-molecule thyroid hormone synthesis inhibitor used to treat hyperthyroidism and Graves' disease. It works by blocking thyroid peroxidase, preventing the formation of thyroid hormones T3 and T4. PTU is particularly valuable in early pregnancy and thyroid storm due to its additional inhibition of peripheral conversion of T4 to T3.
As an approaching LOE product with moderate competitive pressure (30%), the team is likely focused on lifecycle extension, patient retention, and efficient operations rather than growth investment.
Thyroid Hormone Synthesis Inhibitors
Thyroid Hormone Synthesis Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PTU offers limited career growth potential given its mature, LOE-approaching lifecycle and minimal linked job openings. Roles are primarily operational and maintenance-focused, suited for professionals seeking stability in a niche therapeutic area rather than growth or innovation experience.
Worked on PROPYLTHIOURACIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.